Patents by Inventor Fatima KHAN

Fatima KHAN has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PEPTIDE SELECTIVELY BINDING TO CANCER CELL-DERIVED EXOSOME, AND USES THEREOF
    Publication number: 20230295229
    Abstract: The present invention relates to a peptide selectively binding to a cancer cell-derived exosome, and uses thereof, wherein a peptide of ExoPep (CRKVAKG) has been discovered using a phage display technique to discover a peptide with specific binding ability to an exosome derived from cancer cells, and the peptide binds to a cancer cell-derived exosome having a property of moving to a cancer site and a cancer metastasis site, and thus may have the effect of delivering an anticancer drug to the cancer metastasis site.
    Type: Application
    Filed: August 11, 2021
    Publication date: September 21, 2023
    Applicant: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Byung-Heon LEE, Youngji CHAE, Fatima KHAN, Sri Murugan Poongkavithai VADEVOO, Gowri Rangaswamy GUNASSEKARAN
  • Peptides for binding to CD44v6 and use thereof
    Patent number: 11192920
    Abstract: The present invention relates to a peptide bound to CD44v6 and uses for inhibiting cancer metastasis using the same, and the peptide of the present invention specifically binds to CD44v6 and inhibits it, thereby inhibiting cancer cell migration and metastasis. The peptides of the present invention selected two peptides (v6Pep-1 and v6Pep-2) that bind well to cells with high expression of human CD44v6 protein using phage peptide display technology and it was confirmed that it interferes with the binding between c-Met and CD44v6 to inhibit cancer cell migration. The peptide of the present invention is relatively stable in serum and shows a high potential as an anticancer treatment agent that suppresses metastasis due to the progression and migration of cancer in the future.
    Type: Grant
    Filed: December 17, 2018
    Date of Patent: December 7, 2021
    Assignee: KYUNGPOOK NATIONAL, UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Byung-Heon Lee, Fatima Khan
  • PEPTIDES BINDING TO CD44V6 AND USE THEREOF
    Publication number: 20210163535
    Abstract: The present invention relates to a peptide bound to CD44v6 and uses for inhibiting cancer metastasis using the same, and the peptide of the present invention specifically binds to CD44v6 and inhibits it, thereby inhibiting cancer cell migration and metastasis. The peptides of the present invention selected two peptides (v6Pep-1 and v6Pep-2) that bind well to cells with high expression of human CD44v6 protein using phage peptide display technology and it was confirmed that it interferes with the binding between c-Met and CD44v6 to inhibit cancer cell migration. The peptide of the present invention is relatively stable in serum and shows a high potential as an anticancer treatment agent that suppresses metastasis due to the progression and migration of cancer in the future.
    Type: Application
    Filed: December 17, 2018
    Publication date: June 3, 2021
    Applicant: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Byung-Heon LEE, Fatima KHAN